Year Archives - Arvinas

Physicochemical Property Determinants of Oral Absorption for PROTAC® Protein Degraders

Protein Degradation Therapeutics: PROTAC® Drug Discovery at Arvinas

Small molecule PROTAC® hijacking and structural characterization of an E3 ligase, KLHDC2, for targeted protein degradation

Discovery & Optimization of PROTAC® Molecules That Selectively Reduce Mutant Huntingtin

Oral PROTAC® Degrader Molecules to Selectively Clear Proteins in Neurodegenerative Diseases

The Arvinas PROTAC® Discovery Engine: PROTAC Biophysical Characterization Fuels The Discovery Of Target And E3 Ligase Ligands For Optimized PROTAC Degrader Molecules

KRAS-Targeted PROTAC® Degraders are Broadly Efficacious Against KRAS Dependent Tumor Models

High throughput screening techniques to inform on compound liability and solubility to advance the PROTAC® platform

A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – PLS

Structural insights into PROTAC®-induced proximity

;